Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: Mechanism of action and clinical activity

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 7, 2009, Pages 805-812

  Lech Maranda, Ewa ^a   Korycka, Anna ^a   Robak, Tadeusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Acute leukemia; Clinical application; Clofarabine; Mechanism of action; Purine nucleoside analogues

Indexed keywords

CLADRIBINE; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; ADENINE NUCLEOTIDE; ANTINEOPLASTIC AGENT; ARABINONUCLEOSIDE; NUCLEOSIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY; BONE MARROW SUPPRESSION; CHEMOTHERAPY INDUCED EMESIS; CHILDHOOD LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; ERYTHEMA; FEBRILE NEUTROPENIA; FLUSHING; HALF LIFE TIME; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; IRRITABILITY; LEUKEMIA REMISSION; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYALGIA; MYELODYSPLASTIC SYNDROME; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OPTIMAL DRUG DOSE; PLASMA PROTEIN BINDING; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SOLID TUMOR; STOMATITIS; THROMBOCYTE COUNT; ANIMAL; BLOOD DISEASE; CHEMISTRY;

ADENINE NUCLEOTIDES; ANIMALS; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; CLINICAL TRIALS AS TOPIC; HEMATOLOGIC NEOPLASMS; HUMANS; NUCLEOSIDES;

EID: 68849122744     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709788452586     Document Type: Review

References (47)

1. Tallman, M.S.; Hakimian, D.; Variakojis, D.; Koslow, D.; Sisney, G.A.; Rademaker, A.W.; Rose, E.; Kaul, K. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood, 1992, 80, 2203-9.
2. Robak, T.; Korycka, A.; Kasznicki, M.; Wrzesień-Kuś, A.; Smolewski, P. Purine nucleoside analogues for the treatment of hematological malignancies: Pharmacology and clinical applications. Curr. Cancer Drug Targets, 2005, 5, 421-44.
3. Wendtner, C.M.; Eichhorst, B.F.; Hallek, M.J. Advances in chemotherapy for chronic lymphocytic leukemia. Semin. Hematol., 2004, 41, 224-33.
4. Parker, W.B.; Secrist, J.A. 3rd; Waud, W.R. Purine nucleoside antimetabolites in development for the treatment of cancer. Curr. Opin. Investig. Drugs, 2004, 5, 592-6.
5. Faderl, S.; Gandhi, V.; Keating, M.J.; Jeha, S.; Plunkett, W.; Kantarjian, H.M. The role of clofarabine in hematologic and solid malignancies - development of a next-generation nucleoside analog. Cancer, 2005, 103, 1985-95.
6. Pui, C.H.; Jeha, S.; Kirkpatrick, P. Clofarabine. Nat. Rev. Drug Discov., 2005, 4, 369-70.
7. Lindemalm, S.; Liliemark, J.; Juliusson, G.; Larsson, R.; Albertioni, F. Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia. Cancer Lett., 2004, 210, 171-7.
8. Bonate, P.L.; Arthaud, L.; Cantrell, W.R. Jr; Stephenson, K.; Secrist, J.A. 3rd; Weitman, S. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat. Rev. Drug Discov., 2006, 5, 855-63.
9. Van den Neste, E.; Cardoen, S.; Offner, F.; Bontemps, F. Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine. Int. J. Oncol., 2005, 27, 1113-24.
10. Reichelova, V.; Liliemark, J.; Albertioni, F. Liquid chromatographic study of acid stability of 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine, 2-chloro-2'-deoxy-adenosine and related analogues. J. Pharm. Biomed. Anal., 1995, 13, 711-4.
11. Jeha, S.; Gandhi, V.; Chan, K.W.; McDonald, L.; Ramirez, I.; Madden, R.; Rytting, M.; Brandt, M.; Keating, M.; Plunkett, W.; Kantarjian, H. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood, 2004, 103, 784-9.
12. Kline, J.P.; Larson, R. Clofarabine in the treatment of acute myeloid leukemia and acute lymphoblastic leukemia: a review. Expert. Opin. Pharmacother., 2005, 6, 1-8
13. Kantarjian, H.M.; Jeha, S.; Gandhi, V.; Wess, M.; Faderl, S. Clofarabine: past, present, and future. Leuk. Lymphoma, 2007, 48, 1922-30.
14. Harned, T.M.; Gaynon, P.S. Treating refractory leukemias in childhood, role of clofarabine. Ther. Clin. Risk Manag., 2008, 4, 327-36.
15. Carson, D.A.; Wasson, D.B.; Esparza, L.M.; Carrera, C.J.; Kipps, T.J.; Cottam, H.B. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine. Proc. Natl. Acad. Sci. U S A., 1992, 89, 2970-4.
16. Xie, K.C.; Plunkett, W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine. Cancer Res., 1996, 56, 3030-7.
17. Parker, W.B.; Shaddix, S.C.; Rose, L.M.; Shewach, D.S.; Hertel, L.W.; Secrist, J.A. 3rd; Montgomery, J.A.; Bennett, L.L. Jr. Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro-beta-D-ribofuranosyl)adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro-beta-D-ribofuranosyl)adenine in CEM cells. Mol. Pharmacol., 1999, 55, 515-20.
18. King, K.M.; Damaraju, V.L.; Vickers, M.F.; Yao, S.Y.; Lang, T.; Tackaberry, T.E.; Mowles, D.A.; Ng, A.M.; Young, J.D.; Cass, C.E. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Mol. Pharmacol., 2006, 69, 346-53.
19. Pastor-Anglada, M.; Molina-Arcas, M.; Casado, F.J.; Bellosillo, B.; Colomer, D.; Gil, J. Nucleoside transporters in chronic lymphocytic leukaemia. Leukemia, 2004, 18, 385-93.
20. Leung, G.; Tse, Ch-M. The role of mitochondrial and plasma membrane nucleoside transporters in drug toxicity. Expert. Opin. Drug Toxicol., 2007, 3, 1-14.
21. Baldwin, S.A.; Yao, S.Y.; Hyde, R.J.; Ng, A.M.; Foppolo, S.; Barnes, K.; Ritzel, M.W.; Cass, C.E.; Young, J.D. Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J. Biol. Chem., 2005, 280, 15880-7.
22. Bohman, C.; Eriksson, S. Deoxycytidine kinase from human leukemic spleen: preparation and characteristics of homogeneous enzyme. Biochemistry, 1988, 27, 4258-65.
23. Lotfi, K.; Månsson, E.; Spasokoukotskaja, T.; Pettersson, B.; Liliemark, J.; Peterson, C.; Eriksson, S.; Albertioni, F. Biochemical pharmacology and resistance to 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin. Cancer Res., 1999, 5, 2438-44.
24. Zhang, Y.; Secrist, J.A.3rd; Ealick, S.E. The structure of human deoxycytidine kinase in complex with clofarabine reveals key interactions for prodrug activation. Acta Crystallogr. D. Biol. Crystallogr., 2006, 62, 133-9.
25. Arnér, E.S.; Eriksson, S. Mammalian deoxyribonucleoside kinases. Pharmacol. Ther., 1995. 67, 155-86.
26. Eriksson, S.; Arnér, E.; Spasokoukotskaja, T.; Wang, L.; Karlsson, A.; Brosjö, O.; Gunvén, P.; Julusson, G.; Liliemark, J. Properties and levels of deoxynucleoside kinases in normal and tumor cells; implications for chemotherapy. Adv. Enzyme Regul., 1994, 34, 13-25.
27. Xie, C.; Plunkett, W. Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)-adenine in human lymphoblastoid cells. Cancer Res., 1995, 55, 2847-52.
28. Gandhi, V.; Kantarjian, H.; Faderl, S.; Bonate, P.; Du, M.; Ayres, M.; Rios, M.B.; Keating, M.J.; Plunkett, W. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin. Cancer Res., 2003, 9, 6335-42.
29. Bonate, P.L.; Craig, A.; Gaynon, P.; Gandhi, V.; Jeha, S.; Kadota, R.; Lam, G.N.; Plunkett, W.; Razzouk, B.; Rytting, M.; Steinherz, P.; Weitman, S. Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. J. Clin. Pharmacol., 2004, 44, 1309-22.
30. Genini, D.; Adachi, S.; Chao, Q.; Rose, D.W.; Carrera, C.J.; Cottam, H.B.; Carson, D.A.; Leoni, L.M. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood, 2000, 96, 3537-43.
31. Robak, T.; Lech-Maranda, E.; Korycka, A.; Robak, E. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. Curr. Med. Chem., 2006, 13, 3165-3189.
32. Parker, W.B.; Shaddix, S.C.; Chang, C.H.; White, E.L.; Rose, L.M.; Brockman, R.W.; Shortnacy, A.T.; Montgomery, J.A.; Secrist, J.A. 3rd; Bennett, L.L.Jr. Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res., 1991, 51, 2386-94.
33. Pettitt, A.R. Mechanism of action of purine analogues in chronic lymphocytic leukaemia. Br. J. Haematol., 2003, 121, 692-702.
34. Grütter, M.G. Caspases: key players in programmed cell death. Curr. Opin. Struct. Biol., 2000, 10, 649-55.
35. Korycka, A.; Lech-Marańda, E.; Robak, T. Novel purine nucleoside analogues for hematological malignancies. Recent Patents Anticancer Drug Discov., 2008, 3, 123-36.
36. Kantarjian, H.; Gandhi, V.; Cortes, J.; Verstovsek, S.; Du, M.; Garcia-Manero, G.; Giles, F.; Faderl, S.; O'Brien, S.; Jeha, S.; Davis, J.; Shaked, Z.; Craig, A.; Keating, M.; Plunkett, W.; Freireich, E.J. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood, 2003, 102, 2379-86.
37. Kantarjian, H.M.; Gandhi, V.; Kozuch, P.; Faderl, S.; Giles, F.; Cortes, J.; O'Brien, S.; Ibrahim, N.; Khuri, F.; Du, M.; Rios, M.B.; Jeha, S.; McLaughlin, P.; Plunkett, W.; Keating, M. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J. Clin. Oncol., 2003, 21, 1167-73.
38. Kurtzberg, J.; Ernst, T.J.; Keating, M.J.; Gandhi, V.; Hodge, J.P.; Kisor, D.F.; Lager, J.J.; Stephens, C.; Levin, J.; Krenitsky, T.; Elion, G.; Mitchell, B.S. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J. Clin. Oncol., 2005, 23, 3396-403.
39. Jeha, S.; Kantarjian, H. Clofarabine for the treatment of acute lymphoblastic leukemia. Expert Rev. Anticancer Ther., 2007, 7, 113-8.
40. Jeha, S.; Gaynon, P.S.; Razzouk, B.I.; Franklin, J.; Kadota, R.; Shen, V.; Luchtman-Jones, L.; Rytting, M.; Bomgaars, L.R.; Rheingold, S.; Ritchey, K.; Albano, E.; Arceci, R.J.; Goldman, S.; Griffin, T.; Altman, A.; Gordon, B.; Steinherz, L.; Weitman, S.; Steinherz, P. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J. Clin. Oncol., 2006, 24, 1917-23.
41. Gidwani, P.; Ramesh, K.H.; Liu, Y.; Kolb, E.A. The comparison of clofarabine and cytarabine in pediatric relapsed acute lymphoblastic leukemia: a case report. Chemotherapy, 2008, 54, 120-4.
42. Faderl, S.; Gandhi, V.; O'Brien, S.; Bonate, P.; Cortes, J.; Estey, E.; Beran, M,; Wierda, W.; Garcia-Manero, G.; Ferrajoli, A.; Estrov, Z.; Giles, F.J.; Du, M.; Kwari, M.; Keating, M.; Plunkett, W.; Kantarjian, H. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood, 2005, 105, 940-7.
43. Cooper, T.; Ayres, M.; Nowak, B.; Gandhi, V. Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother. Pharmacol., 2005, 55, 361-8.
44. Faderl, S.; Verstovsek, S.; Cortes, J.; Ravandi, F.; Beran, M.; Garcia-Manero, G.; Ferrajoli, A.; Estrov, Z.; O'Brien, S.; Koller, C.; Giles, F.J.; Wierda, W.; Kwari, M.; Kantarjian, H.M. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood, 2006, 108, 45-51.
45. Faderl, S,; Ravandi, F.; Huang, X.; Garcia-Manero, G.; Ferrajoli, A.; Estrov, Z.; Borthakur, G.; Verstovsek, S.; Thomas, D.A.; Kwari, M.; Kantarjian, H.M. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood, 2008, 112, 1638-45.
46. Karp, J.E.; Ricklis, R.M.; Balakrishnan, K.; Briel, J.; Greer, J.; Gore, S.D.; Smith, B.D.; McDevitt, M.A.; Carraway, H.; Levis, M.J.; Gandhi, V. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood, 2007, 110, 1762-9.
47. Uy, G.L.; Tomasson, M.H.; Ruddell, A.; DiPersio, J.F.; Vij, R. The activity and toxicity of low dose clofarabine against relapsed or refractory myeloma. Haematologica, 2006, 91, 1581-2.